Identification of the Endogenous Cannabinoid System through Integrative Pharmacological Approaches

  1. Billy R. Martin
  1. Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia
  1. Dr. Billy R. Martin, Department of Pharmacology and Toxicology, P.O. Box 980613, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298-0613. E-mail: martinb{at}hsc.vcu.edu

Abstract

Scientific progress in the biological sciences increasingly relies on an integration of behavioral, pharmacological, cellular, and molecular approaches, particularly in translating basic research observations into therapeutic potential. The strength of in vivo model systems lies in the direct assessment of physiological function. However, they only allow indirect evidence for mechanism of action. Frequently, in vitro models provide just the opposite. A combination of both in vitro and in vivo approaches are often essential for establishing the underlying mechanisms of a specific pharmacological effect. In recent times, an endogenous cannabinoid system has been characterized due to the combined efforts of chemists, pharmacologists, molecular and cellular biologists, and biochemists. This endogenous cannabinoid system is providing a basis for systematically addressing the pharmacological controversies surrounding marijuana. The description of this endogenous cannabinoid system and the strategies for establishing the physiological function of this system are the subjects of this article.

Footnotes

  • Portions of the research described in this article were supported by National Institute of Drug Abuse Grants DA-03672, DA-05274, and DA-09789.

  • Abbreviations:
    THC
    Δ9-tetrahydrocannabinol
    CB1
    cannabinoid receptor
    SR 141716A
    N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-me thyl-1H-pyrazole-3-carboxamide hydrochloride
    WIN 55,212-2
    (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpho-linylmethyl)pyrrolo-[1,2,3-d,e]-1,4-benzoxazin-6-yl]-1-naphth-alenyl-methanonemesylate
    • Received January 10, 2002.
    • Accepted March 11, 2002.
« Previous | Next Article »Table of Contents